指南与共识骨软组织肉瘤与黑色素瘤

儿童横纹肌肉瘤临床试验中的分子检测以改善风险分层和结局:欧洲儿童软组织肉瘤研究组、儿童肿瘤组与德国软组织肉瘤研究组的共识观点

Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
指南 / 共识 · Eur J Cancer · 2022-07-12

横纹肌肉瘤(RMS)是18岁以下儿童和青少年最常见的软组织肉瘤,年发病率1-2/百万。欧洲和北美临床试验的风险分层已从临床病理特征转向纳入PAX3/7-FOXO1融合基因状态替代腺泡组织学。国际工作组通过国际软组织肉瘤联盟提出协调方案,评估特定遗传异常并整合分子与临床数据。共识推荐评估MYOD1-LR122R突变以升级风险,因该突变与梭形/硬化型RMS及罕见经典胚胎组织学RMS的不良结局相关。

要点

  • 推荐评估MYOD1-LR122R突变以升级风险,该突变与梭形/硬化型RMS及罕见经典胚胎组织学RMS的不良结局相关。
  • PAX3/7-FOXO1融合基因状态已替代腺泡组织学纳入欧洲和北美临床试验的风险分层。
  • 建议在诊断/复发时进行肿瘤DNA/RNA分析并尽可能连续分析血浆样本,以验证和识别分子生物标志物。

核心结论

  • 国际工作组提出协调方案,评估特定遗传异常并整合分子与临床数据,以改善RMS患者的治疗分配、管理和结局。

研究设计与样本

  • 欧洲儿童软组织肉瘤研究组、儿童肿瘤组与德国软组织肉瘤研究组的共识观点,通过国际软组织肉瘤联盟提出协调方案。

主要发现

  • RMS年发病率为1-2/百万(18岁以下儿童和青少年)。
  • 欧洲和北美临床试验的风险分层已纳入PAX3/7-FOXO1融合基因状态替代腺泡组织学。
  • MYOD1-LR122R突变与梭形/硬化型RMS和罕见经典胚胎组织学RMS的不良结局相关。

关键数值与推荐

  • 推荐评估MYOD1-LR122R突变以升级风险。
  • 建议评估TP53及其他癌症易感基因的致病/可能致病种系变异。
  • 建议在诊断/复发时进行肿瘤DNA/RNA分析并尽可能连续分析血浆样本。
  • 对PAX3/7-FOXO1以外的罕见融合基因进行前瞻性分析将产生与结局相关的新数据。
  • 评估TP53突变和CDK4扩增可能确认其预后价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children/adolescents less than 18 years of age with an annual incidence of 1-2/million. Inter/intra-tumour heterogeneity raise challenges in clinical, pathological and biological research studies. Risk stratification in European and North American clinical trials previously relied on clinico-pathological features, but now, incorporates PAX3/7-FOXO1-fusion gene status in the place of alveolar histology. International working groups propose a coordinated approach through the INternational Soft Tissue SaRcoma ConsorTium to evaluate the specific genetic abnormalities and generate and integrate molecular and clinical data related to patients with RMS across different trial settings. We review relevant data and present a consensus view on what molecular features should be assessed. In particular, we recommend the assessment of the MYOD1-LR122R mutation for risk escalation, as it has been associated with poor outcomes in spindle/sclerosing RMS and rare RMS with classic embryonal histopathology. The prospective analyses of rare fusion genes beyond PAX3/7-FOXO1 will generate new data linked to outcomes and assessment of TP53 mutations and CDK4 amplification may confirm their prognostic value. Pathogenic/likely pathogenic germline variants in TP53 and other cancer predisposition genes should also be assessed. DNA/RNA profiling of tumours at diagnosis/relapse and serial analyses of plasma samples is recommended where possible to validate potential molecular biomarkers, identify new biomarkers and assess how liquid biopsy analyses can have the greatest benefit. Together with the development of new molecularly-derived therapeutic strategies that we review, a synchronised international approach is expected to enhance progress towards improved treatment assignment, management and outcomes for patients with RMS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hettmer S, Linardic CM, Kelsey A, et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022. PMID: 35839732. doi:10.1016/j.ejca.2022.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。